PURPOSE: To improve the detection of prostate cancer, especially in pre-biopsied patients, a guided biopsy based on radiologic findings is an option. We addressed the question, whether the combination of multiparametric MRI and computerized transrectal ultrasound (C-TRUS) improves the detection of prostate cancer. METHODS: Twenty patients suspicious of having prostate cancer were included. Seventeen patients were pre-biopsied once or more. Each patient was examined by multiparametric MRI and C-TRUS, followed by a guided transrectal prostate biopsy series. Patients were stratified in a "low-risk" and "high-risk" group. The results were analyzed using descriptive statistics. RESULTS: In 58 % (11 pat.) of patients, prostate cancer was found. In the "high-risk" group, biopsy in 73 % (8 pat.) of patients was positive for prostate cancer. All prostate cancer patients were found by C-TRUS-guided biopsies, whereas MRI did not reveal cancer in 27 %. 72 % (8 pat.) of patients had undergone radical prostatectomy. 65 % (6 pat.) had higher tumor stages after prostatectomy and 62.5 % (5 pat.) had higher Gleason-score. CONCLUSIONS: Combination of multiparametric MRI and C-TRUS seems to improve detection of prostate cancer, especially in high-risk patients. Detection rates of C-TRUS in this study could confirm those of the primary C-TRUS studies. The benefit of MRI is the additional visualization of the tumor extension. The technique is an option for pre-biopsied patients. Both imaging methods often fail to predict correct tumor stage, but further studies are necessary.
PURPOSE: To improve the detection of prostate cancer, especially in pre-biopsied patients, a guided biopsy based on radiologic findings is an option. We addressed the question, whether the combination of multiparametric MRI and computerized transrectal ultrasound (C-TRUS) improves the detection of prostate cancer. METHODS: Twenty patients suspicious of having prostate cancer were included. Seventeen patients were pre-biopsied once or more. Each patient was examined by multiparametric MRI and C-TRUS, followed by a guided transrectal prostate biopsy series. Patients were stratified in a "low-risk" and "high-risk" group. The results were analyzed using descriptive statistics. RESULTS: In 58 % (11 pat.) of patients, prostate cancer was found. In the "high-risk" group, biopsy in 73 % (8 pat.) of patients was positive for prostate cancer. All prostate cancerpatients were found by C-TRUS-guided biopsies, whereas MRI did not reveal cancer in 27 %. 72 % (8 pat.) of patients had undergone radical prostatectomy. 65 % (6 pat.) had higher tumor stages after prostatectomy and 62.5 % (5 pat.) had higher Gleason-score. CONCLUSIONS: Combination of multiparametric MRI and C-TRUS seems to improve detection of prostate cancer, especially in high-risk patients. Detection rates of C-TRUS in this study could confirm those of the primary C-TRUS studies. The benefit of MRI is the additional visualization of the tumor extension. The technique is an option for pre-biopsied patients. Both imaging methods often fail to predict correct tumor stage, but further studies are necessary.
Authors: M Roethke; A G Anastasiadis; M Lichy; M Werner; P Wagner; S Kruck; Claus D Claussen; A Stenzl; H P Schlemmer; D Schilling Journal: World J Urol Date: 2011-04-22 Impact factor: 4.226
Authors: Jochen Walz; Markus Graefen; Felix K-H Chun; Andreas Erbersdobler; Alexander Haese; Thomas Steuber; Thorsten Schlomm; Hartwig Huland; Pierre I Karakiewicz Journal: Eur Urol Date: 2006-03-29 Impact factor: 20.096
Authors: T Loch; I Leuschner; C Genberg; K Weichert-Jacobsen; F Küppers; M Retz; J Lehmann; E Yfantis; M Evans; V Tsarev; M Stöckle Journal: Urologe A Date: 2000-07 Impact factor: 0.639
Authors: Klaus Eichler; Susanne Hempel; Jennifer Wilby; Lindsey Myers; Lucas M Bachmann; Jos Kleijnen Journal: J Urol Date: 2006-05 Impact factor: 7.450
Authors: Carsten-H Ohlmann; Michael Stöckle; Peter Albers; Heinz Schmidberger; Martin Härter; Glen Kristiansen; Peter Martus; Stefan Wellek; Roswitha Bussar-Maatz; Thomas Wiegel Journal: Urologe A Date: 2016-03 Impact factor: 0.639
Authors: Jean-Michel Correas; Ethan J Halpern; Richard G Barr; Sangeet Ghai; Jochen Walz; Sylvain Bodard; Charles Dariane; Jean de la Rosette Journal: World J Urol Date: 2020-04-18 Impact factor: 4.226